Table 1. Patient characteristics at the 2018 index visit.
| Variables | Value |
|---|---|
| Age (years), mean ± SD | 62.2±9.9 |
| Male sex, n (%) | 105/152 (69.1) |
| BMI (kg/m2), mean ± SD | 28.5±4.9 |
| Ischaemic aetiology, n (%) | 64/152 (42.1) |
| Risk factors, n (%) | |
| Dyslipidaemia | 107/152 (70.4) |
| Hypertension | 73/150 (48.7) |
| Obesity | 53/142 (37.3) |
| Ex-smoker | 56/152 (36.8) |
| Current smoker | 24/152 (15.8) |
| Diabetes mellitus | 58/151 (38.4) |
| NYHA class*, n (%) | |
| I | 9/151 (6.0) |
| II | 107/151 (70.9) |
| III | 31/151 (20.5) |
| IV | 4/151 (2.6) |
| SBP (mmHg), mean ± SD | 116.1±17.3 |
| DBP (mmHg), mean ± SD | 67.8±10.4 |
| HR (bpm), mean ± SD | 67.8±10.8 |
| BNP (pg/mL), median (IQR) | 156.0 (91.5–290.0) |
| LVEF (%), median (IQR) | 28.0 (22.0–33.0) |
| Creatinine (mg/dL), median (IQR) | 0.9 (0.8–1.1) |
| CKD stage, n (%) | |
| 1 | 33/131 (25.2) |
| 2 | 50/131 (38.2) |
| 3 | 37/131 (28.2) |
| 4 | 7/131 (5.3) |
| 5 | 0/31 (0.0) |
| Potassium (mmol/L), mean ± SD | 4.5±0.6 |
| Medication, n (%) | |
| ACEis | 116/152 (76.3) |
| ARBs | 24/152 (15.8) |
| BBs | 144/152 (94.7) |
| MRAs | 134/152 (88.2) |
| ARNi | 7/152 (4.6) |
*, the data for NYHA class reflect the status of patients at the time of index visit. Patients were required to have displayed at least NYHA class II symptoms at any point of the follow-up period. BMI, body mass index; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; CKD, chronic kidney disease; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β-blocker; MRA, mineralocorticoid receptor antagonist; ARNi, angiotensin receptor-neprilysin inhibitor; SD, standard deviation; IQR, interquartile range.